The DOCK9 Knockout HEK293T Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population for studying DOCK9-dependent signaling in a widely used human embryonic kidney background. This product consists of a heterogeneous pool of HEK293T cells subjected to CRISPR/Cas9-mediated gene disruption, resulting in a loss-of-function model that captures diverse knockout genotypes. The polyclonal format avoids clonal selection bias and enables robust phenotypic analysis directly in a mixed population.
HEK293T cells are epithelial cells derived from human embryonic kidney, engineered to stably express the SV40 large T antigen. This modification confers high transfection efficiency and supports episomal replication of plasmids containing the SV40 origin, making the cell line exceptionally well-suited for heterologous protein expression, viral packaging, and cell biology assays. The robust growth characteristics and consistent experimental performance of HEK293T cells establish a reliable platform for gene-edited knockout studies.
DOCK9 encodes a guanine nucleotide exchange factor that specifically activates the small GTPase Cdc42 by promoting GDP-to-GTP exchange. Active Cdc42 binds and stimulates downstream effectors including PAK1 and the N-WASP?CArp2/3 complex, driving actin nucleation and polymerization. This signaling axis is regulated by upstream factors such as the EGF receptor, integrin-mediated adhesion, PIP3, and Rac1, and it controls critical processes like cell adhesion, migration, and membrane trafficking. Disruption of DOCK9 therefore impairs Cdc42-mediated cytoskeletal reorganization.
In the HEK293T context, loss of DOCK9 provides a simplified system to interrogate Cdc42-dependent actin dynamics without neuronal-specific complexity. The knockout affects fundamental epithelial cell behaviors such as spreading, polarization, and motility, offering insights into cell biological mechanisms that are broadly conserved. Because the polyclonal population contains a range of edited alleles, researchers can assess functional penetrance and variability, which is particularly useful for studying pathway robustness and compensatory mechanisms.
Typical applications include investigation of Cdc42 signaling cascades, quantitative phalloidin staining for F-actin, transwell or wound-healing migration assays, and drug screening for modulators of Rho GTPase pathways. Users can validate DOCK9 knockout via Western blotting for DOCK9, Cdc42, and phospho-PAK, perform Cdc42 activation assays using GST-PBD pull-downs, and analyze downstream transcriptional effects by RT-qPCR. For further information or technical support, please contact Ascent Research.
